Company Filing History:
2 out of 948 
1 out of 168 
Years Active: 2022-2023
Title: Yasuo Sugitani: Innovator in GPC3-Targeting Drug Therapy
Introduction
Yasuo Sugitani is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer therapy, particularly through his work on GPC3-targeting drugs. With a total of 2 patents, Sugitani's innovations are paving the way for more effective cancer treatments.
Latest Patents
Sugitani's latest patents focus on methods for determining the efficacy of GPC3-targeting drug therapy for cancer patients. One patent describes a method for assessing the effectiveness of GPC3-targeting drug therapy before its initiation or during its continuation. This method involves analyzing the number of immunocytes or the expression level of specific molecules in biological samples from patients. The second patent provides a method for determining the efficacy of a GPC3-targeting therapeutic agent specifically for liver cancer patients. It outlines how to ascertain the effectiveness of the therapeutic agent based on the expression level of GPC3 per tumor cell.
Career Highlights
Throughout his career, Yasuo Sugitani has worked with notable companies such as Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in drug development and cancer therapy.
Collaborations
Sugitani has collaborated with esteemed colleagues, including Toshihiko Ohtomo and Takayoshi Tanaka. These partnerships have further enhanced his research and development efforts in the field of cancer treatment.
Conclusion
Yasuo Sugitani's innovative work in GPC3-targeting drug therapy represents a significant advancement in cancer treatment. His patents and collaborations highlight his commitment to improving patient outcomes through targeted therapies.